Skip to Content

'
Ala Abudayyeh

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of General Internal Medicine, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Office Address

The University of Texas MD Anderson Cancer Center
1400 Pressler Street
Unit Number: 1465
Houston, TX 77030
Room Number: FCT13.5000
Phone: 713 745-4516
Fax: 713 563-4491
Email: aabudayyeh@mdanderson.org

Education & Training

Degree-Granting Education

2003 University of Texas-Houston Medical School, Houston, TX, MD, Internal Medicine
1999 Baylor University, Waco, TX, BS, Magna Cum Laude, Biology

Postgraduate Training

6/2009-8/2011 Nephrology Fellowship, Nephrology, Baylor College of Medicine, Houston, TX
6/2004-6/2006 Resident, Internal Medicine, Baylor College of Medicine, Houston, TX
8/2003-6/2006 Internal Medicine Resident, Baylor College of Medicine, Houston, TX

Board Certifications

2011 American Board of Internal Medicine

Selected Publications

Peer-Reviewed Original Research Articles

1. Maliakal P, Abdelrahim M, Sankpal UT, Maliakal C, Baker CH, Safe S, Herrera LJ, Abudayyeh A, Kaja S, Basha R. Chemopreventive effects of tolfenamic acid against esophageal tumorigenesis in rats. Invest New Drugs 30(3):853-61, 6/2012. e-Pub 1/4/2011. PMID: 21197621.
2. Colon J, Basha MR, Madero-Visbal R, Konduri S, Baker CH, Herrera LJ, Safe S, Sheikh-Hamad D, Abudayyeh A, Alvarado B, Abdelrahim M. Tolfenamic acid decreases c-Met expression through Sp proteins degradation and inhibits lung cancer cells growth and tumor formation in orthotopic mice. Invest New Drugs 29(1):41-51, 2/2011. e-Pub 10/2009. PMID: 19851711.
3. Chintharlapalli S, Papineni S, Abdelrahim M, Abudayyeh A, Jutooru I, Chadalapaka G, Wu F, Mertens-Talcott S, Vanderlaag K, Cho SD, Smith R, Safe S. Oncogenic microRNA-27a is a target for anticancer agent methyl 2-cyano-3,11-dioxo-18beta-olean-1,12-dien-30-oate in colon cancer cells. Int J Cancer 125(8):1965-74, 10/2009. PMCID: PMC2766353.
4. Papineni S, Chintharlapalli S, Abdelrahim M, Lee SO, Burghardt R, Abudayyeh A, Baker C, Herrera L, Safe S. Tolfenamic acid inhibits esophageal cancer through repression of specificity proteins and c-Met. Carcinogenesis 30(7):1193-201, 7/2009. e-Pub 4/2009. PMCID: PMC2704282.
5. Liu X, Abdelrahim M, Abudayyeh A, Lei P, Safe S. The nonsteroidal anti-inflammatory drug tolfenamic acid inhibits BT474 and SKBR3 breast cancer cell and tumor growth by repressing erbB2 expression. Mol Cancer Ther 8(5), May 2009. e-Pub 5/2009.
6. Cho SD, Chintharlapalli S, Abdelrahim M, Papineni S, Liu S, Guo J, Lei P, Abudayyeh A. Safe S. 5,5'-Dibromo-bis(e'-indolyl) methane induces Kruppel-like factor 4 and p21 in colon cancer cells. Mol Cancer Ther. 8(3):533-42, 3/2009.
7. Konduri S, Colon J, Baker CH, Safe S, Abbruzzese JL, Abudayyeh A, Basha MR, Abdelrahim M. Tolfenamic acid enhances pancreatic cancer cell and tumor response to radiation therapy by inhibiting survivin protein expression. Mol Cancer Ther 8(3):533-42, 3/2009. e-Pub 3/2009. PMID: 19258429.

Last updated: 7/18/2014